Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Cohbar Inc (CWBR) USD0.001

Sell:$1.47 Buy:$1.50 Change: $0.07 (4.90%)
Market closed |  Prices as at close on 21 October 2019 | Switch to live prices |
Change: $0.07 (4.90%)
Market closed |  Prices as at close on 21 October 2019 | Switch to live prices |
Change: $0.07 (4.90%)
Market closed |  Prices as at close on 21 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CohBar, Inc. (CohBar) is engaged in the research and development of mitochondria-based therapeutics (MBTs), a class of drugs with potential for the treatment of diseases associated with aging. MBTs originate from the discovery of a group of peptides encoded within the genome of mitochondria. The Company's development of mitochondrial-derived peptides (MDPs) into MBTs offers the potential to address a range of diseases including type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders. MDPs represent a diverse and largely unexplored collection of peptides. MOTS-c is an MDP, which indicates that it plays a role in the regulation of metabolism. The Company is engaged in the research on MOTS-c and its analogs as its lead program. The Company's academic collaborators have discovered various other MDPs with similar mitochondrial origin to the MDP, humanin, which the Company refers to as small humanin-like peptides (SHLPs).

Contact details

1455 Adams Dr Ste 2050
United States
+1 (650) 4467888

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$61.29 million
Shares in issue:
42.86 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Albion Fitzgerald
    Independent Chairman of the Board
  • Steven Engle
    Chief Executive Officer, Director
  • Jeffrey Biunno
    Chief Financial Officer, Treasurer, Secretary
  • Jon Stern
    Chief Operating Officer, Director
  • Kenneth Cundy
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.